stoxline Quote Chart Rank Option Currency Glossary
  
Oncternal Therapeutics, Inc. (ONCT)
9  0.68 (8.17%)    03-28 16:00
Open: 8
High: 9.25
Volume: 14,511
  
Pre. Close: 8.32
Low: 8
Market Cap: 27(M)
Technical analysis
2024-03-28 4:53:23 PM
Short term     
Mid term     
Targets 6-month :  10.99 1-year :  12.39
Resists First :  9.41 Second :  10.6
Pivot price 8.46
Supports First :  7.48 Second :  6.22
MAs MA(5) :  8.33 MA(20) :  8.77
MA(100) :  8.42 MA(250) :  7.44
MACD MACD :  -0.3 Signal :  -0.3
%K %D K(14,3) :  37.7 D(3) :  29.3
RSI RSI(14): 53.5
52-week High :  16.39 Low :  5.19
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ONCT ] has closed below upper band by 28.8%. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.26 - 9.29 9.29 - 9.34
Low: 7.91 - 7.95 7.95 - 7.99
Close: 8.93 - 8.99 8.99 - 9.06
Company Description

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Headline News

Sun, 10 Mar 2024
Oncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line - Simply Wall St

Fri, 08 Mar 2024
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript - Yahoo Finance

Thu, 07 Mar 2024
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire

Thu, 07 Mar 2024
Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript - Seeking Alpha

Thu, 07 Mar 2024
Oncternal Therapeutics: Q4 Earnings Snapshot - Quartz

Sun, 03 Mar 2024
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth? - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 3 (M)
Held by Insiders 2.66e+006 (%)
Held by Institutions 8.4 (%)
Shares Short 25 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -3 %
Return on Assets (ttm) 244.4 %
Return on Equity (ttm) -49.5 %
Qtrly Rev. Growth 785000 %
Gross Profit (p.s.) 53.79
Sales Per Share -63.33
EBITDA (p.s.) 0
Qtrly Earnings Growth -13.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -32 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales -0.15
Price to Cash Flow 1.21
Stock Dividends
Dividend 0
Forward Dividend 16040
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android